• STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
  • Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
  • Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals
  • FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia
  • Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma
  • Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma
  • Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma
  • EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma
  • Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients
  • Patient Power, Winship Cancer Institute Partnered for Myeloma Town Hall Meeting
  • Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma
  • Leukogene Therapeutics Awarded $2M to Advance Compound for Treatment-resistant Multiple Myeloma